Clinical investigation of drug therapy for cases of detrusor hyperactivity with impaired contractile function

We assessed the efficacy and safety of a 1adrenoceptor antagonist (Urapidil) alone or combined with an antimuscarinic (oxybutynin or propiverine) in patients diagnosed with detrusor hyperactivity with impaired contractile function (DHIC). Forty patients with urodynamically proven DHIC were stratified into 2 groups, namely group 1 receiving Urapidil only and group 2 receiving Urapidil plus oxybutynin or propiverine for a 12-week treatment regimen. A total of 40 patients, including 16 in group 1 and 24 in group 2 were treated and 40 (100.0%) completed the 12 weeks of treatment. Significant improvement was noted in both group 1 (75.0%) and group 2 (62.5%) after treatment. Voiding difficulty and urinary urgency improved significantly in all patients of both group 1 and group 2. The results of this study suggest that a i-adrenoceptor antagonist alone or combined with an antimuscarinic represents an effective and relatively safe treatment modality for patients with DHIC.